A changing treatment landscape for multiple sclerosis: challenges and opportunities.
about
The Therapeutic Potential of the Ketogenic Diet in Treating Progressive Multiple SclerosisGuidelines for the use of magnetic resonance imaging in diagnosing and monitoring the treatment of multiple sclerosis: recommendations of the Swedish Multiple Sclerosis Association and the Swedish Neuroradiological SocietyCirculating miR-150 in CSF is a novel candidate biomarker for multiple sclerosisImmune Tolerance Induction against Experimental Autoimmune Encephalomyelitis (EAE) Using A New PLP-B7AP Conjugate that Simultaneously Targets B7/CD28 Costimulatory Signal and TCR/MHC-II Signal.Antiepileptic and Antidepressive Polypharmacy in Patients with Multiple Sclerosis.Bifunctional Peptide Inhibitors Suppress Interleukin-6 Proliferation and Ameliorates Murine Collagen-Induced ArthritisChanges in first-line injectable disease-modifying therapy for multiple sclerosis: predictors of non-adherence, switching, discontinuation, and interruption of drugs.Comparative analysis of first-year fingolimod and natalizumab drug discontinuation among Swedish patients with multiple sclerosis.Reprogramming the Local Lymph Node Microenvironment Promotes Tolerance that Is Systemic and Antigen SpecificComparative Effectiveness of Rituximab and Other Initial Treatment Choices for Multiple Sclerosis.Polyplexes assembled from self-peptides and regulatory nucleic acids blunt toll-like receptor signaling to combat autoimmunity.Improved treatment satisfaction after switching therapy to rituximab in relapsing-remitting MS.Engineering Immunological Tolerance Using Quantum Dots to Tune the Density of Self-Antigen Display.In Situ-Based Gels for Nose to Brain Delivery for the Treatment of Neurological Diseases.
P2860
Q26769966-8B38DC11-6392-4566-B00C-AC4C99AFD168Q31123447-504CC623-EAB6-481C-B139-AB3DE40333D6Q34524908-BA656EA6-478B-44FE-8F95-1DC7ECF874ADQ35794350-7E7CB38C-71C4-4858-93C7-8957B059B581Q35843867-9E93FE00-21A5-41C9-9784-AACC57322D6EQ35915683-48CE33AC-63BB-4772-A6E1-70FD5DC689DEQ39025672-0B9B65B4-5E2B-4112-934C-EFD65E777233Q41003368-F20B595E-E244-4E30-9063-E484A4A7814DQ41101351-A8593809-B22E-4557-B805-0D7B7D8ADF20Q47198260-C981694C-E26B-487F-850D-C781A36E3D4DQ48016268-D9132DD6-DB85-4D6A-A2DC-69154C4F3D94Q51750570-C7FEB5CD-4171-4E3B-9EAA-8E22BE905D38Q52674872-E21C8F4A-7F9A-4192-A30A-501F18568AC1Q53697270-63C68A33-F6A6-4BCB-A47C-690A6852B57A
P2860
A changing treatment landscape for multiple sclerosis: challenges and opportunities.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
A changing treatment landscape for multiple sclerosis: challenges and opportunities.
@en
type
label
A changing treatment landscape for multiple sclerosis: challenges and opportunities.
@en
prefLabel
A changing treatment landscape for multiple sclerosis: challenges and opportunities.
@en
P2860
P356
P1476
A changing treatment landscape for multiple sclerosis: challenges and opportunities.
@en
P2093
P2860
P304
P356
10.1111/JOIM.12204
P407
P577
2014-03-17T00:00:00Z